Clinical impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of small cell carcinoma of the prostate.
Rev Esp Med Nucl Imagen Mol 2012;
32:193-5. [PMID:
23218515 DOI:
10.1016/j.remn.2012.10.005]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2012] [Revised: 10/03/2012] [Accepted: 10/05/2012] [Indexed: 11/20/2022]
Abstract
Small cell carcinoma of prostate (PSCC) is an uncommon and aggressive type of prostate malignancy with limited data on the use of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in the clinical management of this rare entity. In this report, clinical and imaging findings of a patient with PSCC are presented. We aimed to discuss the role of PET/CT in the evaluation of PSCC in combination with histopathological characteristics of tumor and emphasize the importance of PET/CT in the clinical management of PSCC.
Collapse